

## **Supplementary information file**

## Annex 1. Search terms and review process

### Review 1: BMI data

Pubmed, google scholar, article reference lists, author contacts and country statistical databases were searched for the relevant data. Organisation's online databases such as World Health Organization BMI database was also searched for relevant data.

The following search terms were used. **Obesity OR BMI OR body mass index OR overweight OR weight AND Middle East OR Bahrain OR Egypt OR Iran OR Jordan OR Kuwait OR Lebanon OR Oman OR Saudi Arabia OR Turkey OR Israel OR Morocco OR Tunisia OR United Arab Emirates.**

Data were included if they were presented using World Health Organization cut-offs for normal weight ( $\geq 25$  kg/m<sup>2</sup>), overweight (BMI 25-29.9 kg/m<sup>2</sup>) and obesity (BMI  $\geq 30$  kg/m<sup>2</sup>) by age and sex group for a specific country.

### Review 2: Disease data

Pubmed, google scholar, article reference lists, author contacts and country statistical databases were searched for the relevant data. Organisation's online databases such as Globocan, World Health Organization infobase, international diabetes federation were also searched for relevant data. The most current data were used.

Incidence and mortality data were included if they were presented by age and sex.

The following search terms were used: **Non-communicable disease OR NCD OR coronary heart disease OR stroke OR cardiovascular OR hypertension OR cancer OR diabetes OR type 2 diabetes OR osteoarthritis OR arthritis**

*AND*

**Incidence OR prevalence OR survival OR mortality**

For each diseases incidence, prevalence or mortality data were included if they were presented by age or sex. Survival was rarely presented by age and sex and so a single figure was used for all age groups. Where data were not presented by age and sex for a country then proxy country data were included. Only articles written in English or translated by the article's author were included.

**Annex 2. References of disease incidence, mortality and survival data used for each country.**

Country	Disease	Incidence	Mortality	Survival
Bahrain	Diabetes	Iran proxy	non-terminal	non-terminal
	CHD	Iran proxy	WHO 2008	Iran proxy
	Stroke	Iran proxy	WHO 2008	Turkey proxy in combination with UK data
	Hypertension	Turkey proxy	non-terminal	non-terminal
	Cancers:			
	Breast	Globocan 2008	Globocan 2008	Oman proxy
	Colorectal	Globocan 2008	Globocan 2008	Iran proxy
	Endometrial	Globocan 2008	Globocan 2008	<a href="http://info.cancerresearchuk.org/cancerstats/">http://info.cancerresearchuk.org/cancerstats/</a>
	Kidney	Globocan 2008	Globocan 2008	<a href="http://info.cancerresearchuk.org/cancerstats/">http://info.cancerresearchuk.org/cancerstats/</a>
	Liver	Globocan 2008	Globocan 2008	Lebanon proxy
	Oesophagus	Globocan 2008	Globocan 2008	<a href="http://info.cancerresearchuk.org/cancerstats/">http://info.cancerresearchuk.org/cancerstats/</a>
	Pancreatic	Globocan 2008	Globocan 2008	<a href="http://info.cancerresearchuk.org/cancerstats/">http://info.cancerresearchuk.org/cancerstats/</a>
	Osteoarthritis	UK proxy	non-terminal	non-terminal
Egypt	Diabetes	Iran proxy	non-terminal	non-terminal
	CHD	Iran proxy	WHO 2008	Iran proxy
	Stroke	Iran proxy	WHO 2008	Turkey proxy in combination with UK data
	Hypertension	Turkey proxy	non-terminal	non-terminal
	Cancers:			
	Breast	Globocan 2008	Globocan 2008	Oman proxy
	Colorectal	Globocan 2008	Globocan 2008	Iran proxy
	Endometrial	Globocan 2008	Globocan 2008	<a href="http://info.cancerresearchuk.org/cancerstats/">http://info.cancerresearchuk.org/cancerstats/</a>
	Kidney	Globocan 2008	Globocan 2008	<a href="http://info.cancerresearchuk.org/cancerstats/">http://info.cancerresearchuk.org/cancerstats/</a>
	Liver	Globocan 2008	Globocan 2008	Lebanon proxy
	Oesophagus	Globocan 2008	Globocan 2008	<a href="http://info.cancerresearchuk.org/cancerstats/">http://info.cancerresearchuk.org/cancerstats/</a>
	Pancreatic	Globocan 2008	Globocan 2008	<a href="http://info.cancerresearchuk.org/cancerstats/">http://info.cancerresearchuk.org/cancerstats/</a>
	Osteoarthritis	UK proxy	non-terminal	non-terminal
Iran	Diabetes	Harati et al 2009	non-terminal	non-terminal
	CHD	Unpublished data	WHO 2008	Ghadimi et al 2006
	Stroke	Azarpahoo et al 2010	WHO 2008	Turkey proxy in combination with UK data
	Hypertension	Turkey proxy	non-terminal	non-terminal
	Cancers:			
	Breast	Globocan 2008	Globocan 2008	Oman proxy
	Colorectal	Globocan 2008	Globocan 2008	Iran proxy
	Endometrial	Globocan 2008	Globocan 2008	<a href="http://info.cancerresearchuk.org/cancerstats/">http://info.cancerresearchuk.org/cancerstats/</a>
	Kidney	Globocan 2008	Globocan 2008	<a href="http://info.cancerresearchuk.org/cancerstats/">http://info.cancerresearchuk.org/cancerstats/</a>
	Liver	Globocan 2008	Globocan 2008	Lebanon proxy
	Oesophagus	Globocan 2008	Globocan 2008	<a href="http://info.cancerresearchuk.org/cancerstats/">http://info.cancerresearchuk.org/cancerstats/</a>
	Pancreatic	Globocan 2008	Globocan 2008	<a href="http://info.cancerresearchuk.org/cancerstats/">http://info.cancerresearchuk.org/cancerstats/</a>
	Osteoarthritis	UK proxy	non-terminal	non-terminal

Country	Disease	Incidence	Mortality	Survival
Jordan	Diabetes	Iran proxy	non-terminal	non-terminal
	CHD	Iran proxy	WHO 2008	Iran proxy
	Stroke	Iran proxy	WHO 2008	Turkey proxy in combination with UK data
	Hypertension	Turkey proxy	non-terminal	non-terminal
	Cancers:			
	Breast	Globocan 2008	Globocan 2008	Oman proxy
	Colorectal	Globocan 2008	Globocan 2008	Iran proxy
	Endometrial	Globocan 2008	Globocan 2008	<a href="http://info.cancerresearchuk.org/cancerstats/">http://info.cancerresearchuk.org/cancerstats/</a>
	Kidney	Globocan 2008	Globocan 2008	<a href="http://info.cancerresearchuk.org/cancerstats/">http://info.cancerresearchuk.org/cancerstats/</a>
	Liver	Globocan 2008	Globocan 2008	Lebanon proxy
	Oesophagus	Globocan 2008	Globocan 2008	<a href="http://info.cancerresearchuk.org/cancerstats/">http://info.cancerresearchuk.org/cancerstats/</a>
	Pancreatic	Globocan 2008	Globocan 2008	<a href="http://info.cancerresearchuk.org/cancerstats/">http://info.cancerresearchuk.org/cancerstats/</a>
Osteoarthritis	UK proxy	non-terminal	non-terminal	
Kuwait	Diabetes	Iran proxy	non-terminal	non-terminal
	CHD	Iran proxy	WHO 2008	Iran proxy
	Stroke	Iran proxy	WHO 2008	Turkey proxy in combination with UK data
	Hypertension	Turkey proxy	non-terminal	non-terminal
	Cancers:			
	Breast	Globocan 2008	Globocan 2008	Oman proxy
	Colorectal	Globocan 2008	Globocan 2008	Iran proxy
	Endometrial	Globocan 2008	Globocan 2008	<a href="http://info.cancerresearchuk.org/cancerstats/">http://info.cancerresearchuk.org/cancerstats/</a>
	Kidney	Globocan 2008	Globocan 2008	<a href="http://info.cancerresearchuk.org/cancerstats/">http://info.cancerresearchuk.org/cancerstats/</a>
	Liver	Globocan 2008	Globocan 2008	Lebanon proxy
	Oesophagus	Globocan 2008	Globocan 2008	<a href="http://info.cancerresearchuk.org/cancerstats/">http://info.cancerresearchuk.org/cancerstats/</a>
	Pancreatic	Globocan 2008	Globocan 2008	<a href="http://info.cancerresearchuk.org/cancerstats/">http://info.cancerresearchuk.org/cancerstats/</a>
Osteoarthritis	UK proxy	non-terminal	non-terminal	
Lebanon	Diabetes	Iran proxy	non-terminal	non-terminal
	CHD	Iran proxy	WHO 2008	Iran proxy
	Stroke	Iran proxy	WHO 2008	Turkey proxy in combination with UK data
	Hypertension	Turkey proxy	non-terminal	non-terminal
	Cancers:			
	Breast	Globocan 2008	Globocan 2008	Oman proxy
	Colorectal	Globocan 2008	Globocan 2008	Iran proxy
	Endometrial	Globocan 2008	Globocan 2008	<a href="http://info.cancerresearchuk.org/cancerstats/">http://info.cancerresearchuk.org/cancerstats/</a>
	Kidney	Globocan 2008	Globocan 2008	<a href="http://info.cancerresearchuk.org/cancerstats/">http://info.cancerresearchuk.org/cancerstats/</a>
	Liver	Globocan 2008	Globocan 2008	Yaghi et al 2006
	Oesophagus	Globocan 2008	Globocan 2008	<a href="http://info.cancerresearchuk.org/cancerstats/">http://info.cancerresearchuk.org/cancerstats/</a>
	Pancreatic	Globocan 2008	Globocan 2008	<a href="http://info.cancerresearchuk.org/cancerstats/">http://info.cancerresearchuk.org/cancerstats/</a>
Osteoarthritis	UK proxy	non-terminal	non-terminal	

Country	Disease	Incidence	Mortality	Survival
Oman	Diabetes	Iran proxy	non-terminal	non-terminal
	CHD	Iran proxy	WHO 2008	Iran proxy
	Stroke	Iran proxy	WHO 2008	Turkey proxy in combination with UK data
	Hypertension	Turkey proxy	non-terminal	non-terminal
	Cancers:		2011 (Oman)	
	Breast	Globocan 2008	Globocan 2008	Kumar et al
	Colorectal	Globocan 2008	Globocan 2008	Iran proxy
	Endometrial	Globocan 2008	Globocan 2008	<a href="http://info.cancerresearchuk.org/cancerstats/">http://info.cancerresearchuk.org/cancerstats/</a>
	Kidney	Globocan 2008	Globocan 2008	<a href="http://info.cancerresearchuk.org/cancerstats/">http://info.cancerresearchuk.org/cancerstats/</a>
	Liver	Globocan 2008	Globocan 2008	Lebanon proxy
	Oesophagus	Globocan 2008	Globocan 2008	<a href="http://info.cancerresearchuk.org/cancerstats/">http://info.cancerresearchuk.org/cancerstats/</a>
	Pancreatic	Globocan 2008	Globocan 2008	<a href="http://info.cancerresearchuk.org/cancerstats/">http://info.cancerresearchuk.org/cancerstats/</a>
Osteoarthritis	UK proxy	non-terminal	non-terminal	
Saudi Arabia	Diabetes	Iran proxy	non-terminal	non-terminal
	CHD	Iran proxy	WHO 2008	Iran proxy
	Stroke	Iran proxy	WHO 2008	Turkey proxy in combination with UK data
	Hypertension	Turkey proxy	non-terminal	non-terminal
	Cancers:			
	Breast	Globocan 2008	Globocan 2008	Oman proxy
	Colorectal	Globocan 2008	Globocan 2008	Iran proxy
	Endometrial	Globocan 2008	Globocan 2008	<a href="http://info.cancerresearchuk.org/cancerstats/">http://info.cancerresearchuk.org/cancerstats/</a>
	Kidney	Globocan 2008	Globocan 2008	<a href="http://info.cancerresearchuk.org/cancerstats/">http://info.cancerresearchuk.org/cancerstats/</a>
	Liver	Globocan 2008	Globocan 2008	Lebanon proxy
	Oesophagus	Globocan 2008	Globocan 2008	<a href="http://info.cancerresearchuk.org/cancerstats/">http://info.cancerresearchuk.org/cancerstats/</a>
	Pancreatic	Globocan 2008	Globocan 2008	<a href="http://info.cancerresearchuk.org/cancerstats/">http://info.cancerresearchuk.org/cancerstats/</a>
Osteoarthritis	UK proxy	non-terminal	non-terminal	
Turkey	Diabetes	Iran proxy	non-terminal	non-terminal
	CHD	Iran proxy	WHO 2008	Iran proxy
	Stroke	Iran proxy	WHO 2008	Samanci et al (2004) in combination with UK
	Hypertension	Arici et al (2010)	non-terminal	non-terminal
	Cancers:			
	Breast	Globocan 2008	Globocan 2008	Oman proxy
	Colorectal	Globocan 2008	Globocan 2008	Iran proxy
	Endometrial	Globocan 2008	Globocan 2008	<a href="http://info.cancerresearchuk.org/cancerstats/">http://info.cancerresearchuk.org/cancerstats/</a>
	Kidney	Globocan 2008	Globocan 2008	<a href="http://info.cancerresearchuk.org/cancerstats/">http://info.cancerresearchuk.org/cancerstats/</a>
	Liver	Globocan 2008	Globocan 2008	Lebanon proxy
	Oesophagus	Globocan 2008	Globocan 2008	<a href="http://info.cancerresearchuk.org/cancerstats/">http://info.cancerresearchuk.org/cancerstats/</a>
	Pancreatic	Globocan 2008	Globocan 2008	<a href="http://info.cancerresearchuk.org/cancerstats/">http://info.cancerresearchuk.org/cancerstats/</a>
Osteoarthritis	UK proxy	non-terminal	non-terminal	

### Annex 3 Modelling obesity distribution over time

An individual's body mass index (BMI) is defined as:

$$BMI = \frac{w}{h^2},$$

where  $w$  and  $h$  correspond to individual's weight and height, respectively.  $BMI$  provides a simple measure of a person's "fatness" or "thinness". Although  $BMI$  is measured on a continuous scale, it is grouped in the following five categories:

- 1)  $BMI$ : <18.5 (underweight)
- 2)  $BMI$  from 18.5 to 24.99: (healthy weight)
- 3)  $BMI$  from 25 to 29.99: (overweight)
- 4)  $BMI$  from 30 to 39.99: (obese)
- 5)  $BMI \geq 40$ : (morbidly obese)

Let  $g=1,\dots,5$ , denote  $BMI$  group (lower and larger values of  $g$  correspond to groups with lower and larger values of  $BMI$  on the continuous scale, respectively). Let  $q_g(t)$  be the prevalence of individuals with  $BMI$  values that correspond to group  $g$  at time  $t$ . To ensure that  $q_g(t)$  takes values within  $[0,1]$ , we model  $q_g(t)$  by

$$q_g(t) = \frac{1}{2}[1 + \tanh(\beta_0^g + \beta_1^g t)]. \quad (1)$$

An alternative way to estimate  $q_g(t)$  is through a logistic regression model with percentage for  $BMI$  group  $g$  as the outcome, and time,  $t$ , as the single explanatory variable:

$$\ln\left(\frac{q_g(t)}{1-q_g(t)}\right) = \beta_0^g + \beta_1^g t. \quad (2)$$

By solving equation (2) for  $q_g(t)$  we obtain

$$q_g(t) = \frac{\exp(\beta_0^g + \beta_1^g t)}{1 + \exp(\beta_0^g + \beta_1^g t)}.$$

Equations (1) and (2) are mathematically identical, but (1) provides greater numerical stability. Fitting separate models for the estimation of  $q_g(t)$  for each group  $g$ , does not guarantee that

$$\sum_{g=1}^5 q_g(t) = 1.$$

Thus, to ensure that the estimates of prevalence of individuals in all  $BMI$  groups sum up to 1 for each time  $t$ , we estimate the prevalence of individuals with  $BMI$  values that correspond to group  $g$  at time  $t$  by

$$P_g(t) = \frac{q_g(t)}{\sum_{g=1}^5 q_g(t)}. \quad (3)$$

### **Micro simulation – BMI growth model**

The distribution of BMI in the population is estimated using regression analysis stratified by both sex (S) and age group (A=0-9, 10-19,20-29,...,70-79, 80+). The fitted models are extrapolated to forecast the distribution of BMI groups in the future. For each sex-and-age-group stratum, the set of cross-sectional, time-dependent, discrete distributions of BMI groups,  $D = \{P_g(t)|g = 1, \dots, 5; t > 0\}$ , is used to manufacture BMI growth models for individual members of the population. This is done in a way that guarantees that the cross-

sectional BMI group distributions obtained by simulation under the growth models match the BMI group distributions of the observed data. The details are as follows;

For each such discrete distribution in  $D$ , there is a continuous counterpart. Let  $\beta$  denote BMI in the continuous scale and let  $f(\beta|A, S, t)$  be the probability density function of  $\beta$  for age group  $A$  and sex  $S$  at time  $t$ . Then

$$P_g(t|A, S) = \int_{\beta \in g} f(\beta|A, S, t) d\beta. \quad (4)$$

Equations (3) and (4) both refer to the same quantity. However, equation (4) uses the definition of a probability density function to express the age-and-sex-specific percentage of individuals in BMI group  $g$  at time  $t$ . Equation (3) gives an estimate of this quantity using model (1) for all  $g=0, \dots, 5$ . The cumulative distribution function of  $\beta$  is

$$F(\beta|A, S, t) = \int_0^\beta f(\beta|A, S, t) d\beta. \quad (5)$$

At a time  $t$ , a person with sex  $S$  belonging to the age group  $A$  is said to be on the  $p$ -th percentile of this distribution if  $F(\beta|A, S, t) = p/100$ . Given the cross-sectional information of  $D$ , it is possible to simulate longitudinal trajectories by forming pseudo cohorts within the population. A key requirement for these sets of longitudinal trajectories is that they reproduce the cross-sectional distribution of BMI groups for any year with available data. The method adopted here and in the earlier Foresight report<sup>1</sup> is based on the assumption that people's BMI changes throughout their lives in such a way that they always stay on the same BMI percentile. As they age, individuals move from one age group to another and their BMI changes so that they remain on the same percentile but of a different distribution. This rule is not too far from the truth; and has as a result that relatively fat people stay relatively fat and relatively thin people stay relatively thin. Crucially it meets the important condition that the cross-sectional BMI group distributions obtained by simulation match the BMI group distributions of the observed data. This can be seen as follows:.

When the population's BMI distributions by sex and age are known for all years (by extrapolation of fitted model (3)), a person who is in age group  $A$  and who grows ten year older will at some time move into the next age group  $A'$  and will have a BMI that was described first by the distribution  $f(\beta|A, S, t)$  and then at the later time  $t'$  by the distribution  $f(\beta|A', S, t')$ . If the BMI of that individual is on the  $p^{\text{th}}$  percentile of the BMI distribution, his BMI will change from  $b$  to  $b'$  so that

$$\beta = F^{-1}\left(\frac{p}{100} \middle| A, S, t\right) \quad (6)$$

$$\beta' = F^{-1}\left(\frac{p}{100} \middle| A', S, t'\right) \Rightarrow \beta' = F^{-1}(F(\beta|A, S, t)|A', S, t') \quad (7)$$

Where  $F^{-1}$  is the inverse function of the cumulative distribution function of  $\beta$ . (7) guarantees that the transformation taking the random variable  $b$  to  $b'$  ensures the correct cross-sectional distribution at  $t'$ .

The micro simulation both generates individuals from the BMI distributions of the set  $D$  and, once generated, grows the individual's BMI in a way that is also determined by the set  $D$ . It is possible to implement (6) as a suitably fast algorithm.

---

<sup>1</sup> Foresight report

**Micro simulation: Birth, disease and death models.**

Simulated people are generated with the correct demographic statistics in the simulation's start-year. In this year women are stochastically allocated the number and years of birth of their children – these are generated from known fertility and mother's age at birth statistics (valid in the start-year). If a woman has children then those children are generated as members of the simulation in the appropriate birth year.

In the course of their lives, simulated people can die from one of the BMI related diseases that they might have acquired or from some other cause. The probabilities that a person of a given age and gender dies from a cause other than a BMI related disease are calculated in terms of known death and disease statistics valid in the start-year and are held constant over the course of the simulation. The death rates from BMI related diseases will change as a consequence of the population's changing BMI distribution.



**Annex 4 Projected age-specific BMI distribution for each country**

**Projected BMI distribution for Bahrain 2010-2050**

Year, BMI	2010			2020			2030			2040			2050		
Age, sex	<25	25-30	>30	<25	25-30	>30	<25	25-30	>30	<25	25-30	>30	<25	25-30	>30
20-24, M	0.57	0.23	0.20	0.61	0.15	0.24	0.62	0.09	0.29	0.61	0.05	0.33	0.60	0.03	0.37
20-24, F	0.49	0.28	0.23	0.44	0.29	0.27	0.40	0.30	0.30	0.35	0.31	0.34	0.31	0.32	0.38
25-29, M	0.57	0.23	0.20	0.61	0.15	0.24	0.62	0.09	0.29	0.61	0.05	0.33	0.60	0.03	0.37
25-29, F	0.49	0.28	0.23	0.44	0.29	0.27	0.40	0.30	0.30	0.35	0.31	0.34	0.31	0.32	0.38
30-34, M	0.27	0.40	0.33	0.24	0.44	0.32	0.21	0.48	0.31	0.18	0.52	0.3	0.15	0.55	0.30
30-34, F	0.29	0.34	0.37	0.28	0.37	0.35	0.27	0.40	0.34	0.25	0.43	0.32	0.24	0.46	0.30
35-39, M	0.27	0.40	0.33	0.24	0.44	0.32	0.21	0.48	0.31	0.18	0.52	0.3	0.15	0.55	0.30
35-39, F	0.29	0.34	0.37	0.28	0.37	0.35	0.27	0.40	0.34	0.25	0.43	0.32	0.24	0.46	0.30
40-44, M	0.16	0.36	0.49	0.09	0.30	0.61	0.05	0.25	0.70	0.03	0.21	0.76	0.02	0.18	0.80
40-44, F	0.23	0.28	0.49	0.27	0.26	0.47	0.31	0.25	0.44	0.35	0.23	0.42	0.39	0.22	0.39
45-49, M	0.16	0.35	0.49	0.08	0.30	0.61	0.04	0.26	0.70	0.02	0.22	0.75	0.01	0.20	0.79
45-49, F	0.23	0.28	0.49	0.27	0.26	0.47	0.31	0.25	0.44	0.35	0.23	0.42	0.39	0.22	0.39
50-54, M	0.26	0.36	0.38	0.17	0.35	0.48	0.11	0.34	0.55	0.07	0.33	0.61	0.04	0.32	0.65
50-54, F	0.18	0.30	0.51	0.14	0.30	0.56	0.10	0.29	0.61	0.07	0.29	0.64	0.05	0.28	0.67
55-59, M	0.26	0.36	0.38	0.19	0.31	0.49	0.14	0.27	0.59	0.1	0.24	0.66	0.07	0.21	0.71
55-59, F	0.18	0.29	0.53	0.12	0.25	0.63	0.09	0.22	0.70	0.06	0.19	0.75	0.04	0.17	0.79
60-64, M	0.15	0.56	0.30	0.04	0.59	0.37	0.01	0.57	0.41	0	0.55	0.45	0	0.53	0.47
60-64, F	0.23	0.49	0.28	0.15	0.61	0.23	0.09	0.71	0.20	0.06	0.77	0.17	0.04	0.82	0.14
65-69, M	0.19	0.50	0.32	0.07	0.53	0.40	0.02	0.52	0.45	0.01	0.51	0.48	0	0.5	0.49
65-69, F	0.64	0.14	0.22	0.74	0.08	0.19	0.79	0.04	0.17	0.83	0.02	0.15	0.85	0.01	0.14
70-74, M	0.70	0.24	0.06	0.75	0.21	0.04	0.79	0.19	0.03	0.82	0.17	0.02	0.84	0.15	0.01
70-74, F	0.72	0.26	0.02	0.75	0.25	0	0.75	0.25	0	0.74	0.26	0	0.74	0.26	0
75+, M	0.70	0.24	0.06	0.75	0.21	0.04	0.79	0.19	0.03	0.82	0.17	0.02	0.84	0.15	0.01
75+, F	0.72	0.26	0.02	0.75	0.25	0	0.75	0.25	0	0.74	0.26	0	0.74	0.26	0

**Projected BMI distribution in Egypt 2010-2050**

	2010			2020			2030			2040			2050		
	<25	25-30	>30	<25	25-30	>30	<25	25-30	>30	<25	25-30	>30	<25	25-30	>30
20-24, M	0.64	0.28	0.07	0.7	0.25	0.04	0.75	0.23	0.02	0.78	0.2	0.01	0.81	0.18	0.01
20-24, F	0.56	0.29	0.16	0.7	0.2	0.1	0.8	0.14	0.06	0.86	0.1	0.04	0.91	0.06	0.03
25-29, M	0.52	0.31	0.18	0.74	0.13	0.14	0.84	0.05	0.11	0.89	0.02	0.09	0.92	0.01	0.07
25-29, F	0.4	0.32	0.28	0.67	0.23	0.1	0.78	0.18	0.03	0.84	0.15	0.01	0.87	0.13	0
30-34, M	0.34	0.4	0.26	0.27	0.33	0.39	0.21	0.27	0.52	0.17	0.21	0.62	0.13	0.17	0.69
30-34, F	0.25	0.29	0.46	0.28	0.17	0.55	0.3	0.09	0.61	0.31	0.05	0.64	0.32	0.03	0.65
35-39, M	0.41	0.47	0.12	0.56	0.44	0.01	0.57	0.43	0	0.56	0.44	0	0.54	0.46	0
35-39, F	0.21	0.25	0.54	0.36	0.11	0.53	0.48	0.04	0.48	0.53	0.02	0.45	0.55	0.01	0.44
40-44, M	0.39	0.36	0.25	0.63	0.22	0.16	0.77	0.13	0.1	0.86	0.08	0.06	0.91	0.05	0.04
40-44, F	0.16	0.2	0.64	0.18	0.05	0.77	0.2	0.01	0.78	0.23	0	0.77	0.26	0	0.74
45-49, M	0.33	0.42	0.25	0.49	0.41	0.1	0.58	0.38	0.03	0.62	0.37	0.01	0.62	0.37	0
45-49, F	0.07	0.26	0.67	0.03	0.25	0.72	0.01	0.23	0.76	0	0.22	0.78	0	0.21	0.79
50-54, M	0.38	0.44	0.18	0.56	0.41	0.03	0.6	0.4	0	0.58	0.42	0	0.56	0.44	0
50-54, F	0.14	0.2	0.66	0.19	0.11	0.7	0.25	0.05	0.7	0.31	0.02	0.66	0.37	0.01	0.62
55-59, M	0.27	0.4	0.34	0.27	0.36	0.36	0.28	0.33	0.38	0.29	0.3	0.41	0.3	0.27	0.43
55-59, F	0.08	0.18	0.74	0.02	0.04	0.94	0	0.01	0.99	0	0	1	0	0	1
60-64, M	0.27	0.4	0.34	0.27	0.36	0.36	0.28	0.33	0.38	0.29	0.3	0.41	0.3	0.27	0.43
60-64, F	0.08	0.18	0.74	0.02	0.04	0.94	0	0.01	0.99	0	0	1	0	0	1
65-69, M	0.27	0.4	0.34	0.27	0.36	0.36	0.28	0.33	0.38	0.29	0.3	0.41	0.3	0.27	0.43
65-69, F	0.08	0.18	0.74	0.02	0.04	0.94	0	0.01	0.99	0	0	1	0	0	1
70-74, M	0.27	0.4	0.34	0.27	0.36	0.36	0.28	0.33	0.38	0.29	0.3	0.41	0.3	0.27	0.43
70-74, F	0.08	0.18	0.74	0.02	0.04	0.94	0	0.01	0.99	0	0	1	0	0	1
75+, M	0.27	0.4	0.34	0.27	0.36	0.36	0.28	0.33	0.38	0.29	0.3	0.41	0.3	0.27	0.43
75+, F	0.08	0.18	0.74	0.02	0.04	0.94	0	0.01	0.99	0	0	1	0	0	1

Note: grey highlighting represents simulated data from first previous age group.

**Projected BMI distributions for Iran 2010-2050**

	2010			2020			2030			2040			2050		
	<25	25-30	>30	<25	25-30	>30	<25	25-30	>30	<25	25-30	>30	<25	25-30	>30
20-24, M	0.8	0.15	0.05	0.83	0.11	0.06	0.85	0.07	0.08	0.86	0.05	0.09	0.86	0.04	0.1
20-24, F	0.77	0.16	0.06	0.85	0.1	0.05	0.9	0.06	0.03	0.94	0.04	0.03	0.96	0.02	0.02
25-29, M	0.58	0.31	0.1	0.55	0.32	0.13	0.52	0.32	0.16	0.48	0.32	0.2	0.44	0.32	0.23
25-29, F	0.45	0.33	0.21	0.38	0.33	0.29	0.31	0.32	0.38	0.24	0.3	0.46	0.19	0.29	0.52
30-34, M	0.62	0.28	0.1	0.72	0.2	0.09	0.79	0.13	0.08	0.84	0.09	0.07	0.88	0.06	0.06
30-34, F	0.5	0.31	0.19	0.62	0.21	0.16	0.72	0.14	0.14	0.78	0.1	0.12	0.83	0.06	0.1
35-39, M	0.48	0.37	0.15	0.51	0.32	0.18	0.53	0.27	0.21	0.54	0.22	0.24	0.55	0.18	0.27
35-39, F	0.29	0.37	0.34	0.25	0.32	0.42	0.22	0.28	0.5	0.19	0.24	0.56	0.17	0.21	0.62
40-44, M	0.48	0.37	0.15	0.52	0.3	0.18	0.55	0.24	0.21	0.57	0.19	0.24	0.58	0.14	0.28
40-44, F	0.29	0.39	0.33	0.24	0.42	0.33	0.2	0.45	0.34	0.17	0.48	0.35	0.14	0.51	0.35
45-49, M	0.47	0.37	0.16	0.53	0.28	0.19	0.59	0.2	0.21	0.63	0.14	0.23	0.65	0.1	0.25
45-49, F	0.24	0.39	0.38	0.18	0.4	0.43	0.13	0.41	0.47	0.09	0.41	0.5	0.06	0.41	0.53
50-54, M	0.47	0.38	0.16	0.54	0.29	0.17	0.6	0.22	0.18	0.65	0.16	0.19	0.69	0.12	0.2
50-54, F	0.25	0.37	0.39	0.19	0.35	0.45	0.15	0.34	0.52	0.11	0.32	0.57	0.09	0.3	0.61
55-59, M	0.45	0.39	0.16	0.44	0.38	0.18	0.43	0.37	0.21	0.42	0.35	0.23	0.41	0.34	0.25
55-59, F	0.26	0.36	0.38	0.22	0.32	0.46	0.19	0.28	0.53	0.16	0.24	0.6	0.14	0.21	0.65
60-64, M	0.45	0.38	0.17	0.41	0.36	0.23	0.37	0.34	0.29	0.33	0.32	0.36	0.29	0.29	0.42
60-64, F	0.26	0.35	0.39	0.2	0.28	0.51	0.15	0.23	0.62	0.12	0.19	0.7	0.09	0.15	0.76
65-69, M	0.48	0.39	0.13	0.57	0.32	0.11	0.66	0.25	0.1	0.72	0.19	0.09	0.78	0.14	0.08
65-69, F	0.29	0.3	0.41	0.34	0.19	0.47	0.37	0.11	0.52	0.4	0.06	0.54	0.42	0.03	0.55
70-74, M	0.48	0.39	0.13	0.57	0.32	0.11	0.66	0.25	0.1	0.72	0.19	0.09	0.78	0.14	0.08
70-74, F	0.29	0.3	0.41	0.34	0.19	0.47	0.37	0.11	0.52	0.4	0.06	0.54	0.42	0.03	0.55
75+, M	0.48	0.39	0.13	0.57	0.32	0.11	0.66	0.25	0.1	0.72	0.19	0.09	0.78	0.14	0.08
75+, F	0.29	0.3	0.41	0.34	0.19	0.47	0.37	0.11	0.52	0.4	0.06	0.54	0.42	0.03	0.55

**Projected BMI distribution in Jordan 2010-2050**

	2010			2020			2030			2040			2050		
	<25	25-30	>30	<25	25-30	>30	<25	25-30	>30	<25	25-30	>30	<25	25-30	>30
20-24, M	0.51	0.38	0.11	0.51	0.38	0.11	0.51	0.38	0.11	0.51	0.38	0.11	0.51	0.38	0.11
20-24, F	0.59	0.23	0.19	0.59	0.23	0.19	0.59	0.23	0.19	0.59	0.23	0.19	0.59	0.23	0.19
25-29, M	0.75	0.18	0.07	0.86	0.09	0.05	0.92	0.05	0.03	0.96	0.02	0.02	0.98	0.01	0.01
25-29, F	0.41	0.3	0.29	0.4	0.26	0.34	0.38	0.23	0.38	0.37	0.2	0.43	0.35	0.18	0.47
30-34, M	0.26	0.44	0.3	0.17	0.5	0.33	0.11	0.53	0.36	0.07	0.56	0.38	0.04	0.57	0.39
30-34, F	0.11	0.47	0.42	0.05	0.61	0.34	0.02	0.69	0.29	0.01	0.74	0.25	0	0.77	0.23
35-39, M	0.26	0.44	0.3	0.17	0.5	0.33	0.11	0.53	0.36	0.07	0.56	0.38	0.04	0.57	0.39
35-39, F	0.11	0.47	0.42	0.05	0.61	0.34	0.02	0.69	0.29	0.01	0.74	0.25	0	0.77	0.23
40-44, M	0.12	0.44	0.44	0.05	0.49	0.46	0.02	0.51	0.47	0.01	0.52	0.48	0	0.52	0.48
40-44, F	0.04	0.36	0.6	0.01	0.53	0.46	0	0.6	0.4	0	0.63	0.37	0	0.64	0.36
45-49, M	0.12	0.44	0.44	0.05	0.49	0.46	0.02	0.51	0.47	0.01	0.52	0.48	0	0.52	0.48
45-49, F	0.04	0.36	0.6	0.01	0.53	0.46	0	0.6	0.4	0	0.63	0.37	0	0.64	0.36
50-54, M	0.13	0.54	0.33	0.06	0.68	0.26	0.03	0.75	0.22	0.01	0.8	0.18	0.01	0.84	0.16
50-54, F	0.02	0.29	0.69	0	0.41	0.59	0	0.48	0.52	0	0.5	0.5	0	0.51	0.49
55-59, M	0.13	0.54	0.33	0.06	0.68	0.26	0.03	0.75	0.22	0.01	0.8	0.18	0.01	0.84	0.16
55-59, F	0.02	0.29	0.69	0	0.41	0.59	0	0.48	0.52	0	0.5	0.5	0	0.51	0.49
60-64, M	0.07	0.48	0.46	0.02	0.51	0.47	0	0.52	0.47	0	0.52	0.47	0	0.52	0.48
60-64, F	0.01	0.29	0.69	0	0.38	0.62	0	0.44	0.56	0	0.47	0.53	0	0.49	0.51
65-69, M	0.07	0.48	0.46	0.02	0.51	0.47	0	0.52	0.47	0	0.52	0.47	0	0.52	0.48
65-69, F	0.01	0.29	0.69	0	0.38	0.62	0	0.44	0.56	0	0.47	0.53	0	0.49	0.51
70-74, M	0.05	0.43	0.52	0.01	0.41	0.58	0	0.42	0.58	0	0.43	0.57	0	0.45	0.55
70-74, F	0.01	0.23	0.76	0	0.24	0.76	0	0.25	0.75	0	0.27	0.73	0	0.3	0.7
75+, M	0.05	0.43	0.52	0.01	0.41	0.58	0	0.42	0.58	0	0.43	0.57	0	0.45	0.55
75+, F	0.01	0.23	0.76	0	0.24	0.76	0	0.25	0.75	0	0.27	0.73	0	0.3	0.7

**Projected BMI distribution in Kuwait 2010-2050**

	2010			2020			2030			2040			2050		
	<25	25-30	>30	<25	25-30	>30	<25	25-30	>30	<25	25-30	>30	<25	25-30	>30
20-24, M	0.36	0.35	0.3	0.26	0.38	0.36	0.18	0.4	0.42	0.12	0.41	0.47	0.08	0.42	0.5
20-24, F	0.37	0.38	0.25	0.33	0.42	0.26	0.29	0.45	0.26	0.25	0.49	0.26	0.22	0.52	0.26
25-29, M	0.2	0.44	0.35	0.11	0.48	0.4	0.06	0.5	0.44	0.03	0.51	0.46	0.02	0.51	0.47
25-29, F	0.26	0.39	0.35	0.18	0.43	0.39	0.12	0.45	0.43	0.08	0.47	0.45	0.05	0.48	0.47
30-34, M	0.19	0.4	0.41	0.13	0.4	0.47	0.09	0.39	0.53	0.06	0.38	0.57	0.04	0.37	0.6
30-34, F	0.16	0.37	0.47	0.12	0.39	0.49	0.09	0.4	0.51	0.07	0.41	0.52	0.05	0.41	0.53
35-39, M	0.15	0.39	0.46	0.09	0.37	0.54	0.05	0.35	0.6	0.03	0.34	0.64	0.02	0.32	0.66
35-39, F	0.13	0.35	0.53	0.09	0.34	0.57	0.06	0.34	0.6	0.04	0.34	0.62	0.03	0.33	0.64
40-44, M	0.14	0.37	0.49	0.1	0.34	0.56	0.06	0.31	0.62	0.04	0.29	0.67	0.03	0.26	0.71
40-44, F	0.12	0.27	0.62	0.09	0.25	0.66	0.08	0.23	0.69	0.06	0.21	0.73	0.05	0.2	0.76
45-49, M	0.15	0.36	0.49	0.11	0.33	0.56	0.07	0.3	0.62	0.05	0.27	0.67	0.04	0.25	0.71
45-49, F	0.09	0.25	0.67	0.06	0.22	0.72	0.04	0.2	0.76	0.03	0.17	0.8	0.02	0.15	0.82
50-54, M	0.12	0.35	0.52	0.05	0.33	0.62	0.02	0.33	0.65	0.01	0.35	0.65	0	0.36	0.64
50-54, F	0.04	0.26	0.7	0.01	0.24	0.75	0	0.23	0.77	0	0.23	0.77	0	0.22	0.78
55-59, M	0.14	0.34	0.52	0.05	0.33	0.62	0.02	0.32	0.65	0.01	0.34	0.66	0	0.35	0.65
55-59, F	0.01	0.21	0.78	0	0.18	0.81	0	0.17	0.83	0	0.15	0.85	0	0.14	0.86
60-64, M	0.13	0.44	0.42	0.07	0.45	0.48	0.03	0.45	0.51	0.01	0.45	0.53	0.01	0.45	0.54
60-64, F	0.01	0.22	0.77	0	0.18	0.82	0	0.16	0.84	0	0.14	0.86	0	0.13	0.87
65-69, M	0.14	0.51	0.35	0.07	0.54	0.39	0.04	0.55	0.41	0.02	0.55	0.43	0.01	0.55	0.44
65-69, F	0.04	0.3	0.66	0.01	0.29	0.7	0	0.28	0.71	0	0.28	0.72	0	0.28	0.72
70-74, M	0.14	0.51	0.35	0.07	0.54	0.39	0.04	0.55	0.41	0.02	0.55	0.43	0.01	0.55	0.44
70-74, F	0.04	0.3	0.66	0.01	0.29	0.7	0	0.28	0.71	0	0.28	0.72	0	0.28	0.72
75+, M	0.14	0.51	0.35	0.07	0.54	0.39	0.04	0.55	0.41	0.02	0.55	0.43	0.01	0.55	0.44
75+, F	0.04	0.3	0.66	0.01	0.29	0.7	0	0.28	0.71	0	0.28	0.72	0	0.28	0.72

**Projected BMI distribution in Lebanon 2010-2050**

	2010			2020			2030			2040			2050		
	<25	25-30	>30	<25	25-30	>30	<25	25-30	>30	<25	25-30	>30	<25	25-30	>30
20-24, M	0.51	0.38	0.11	0.51	0.38	0.11	0.51	0.38	0.11	0.51	0.38	0.11	0.51	0.38	0.11
20-24, F	0.59	0.23	0.19	0.59	0.23	0.19	0.59	0.23	0.19	0.59	0.23	0.19	0.59	0.23	0.19
25-29, M	0.31	0.44	0.25	0.13	0.45	0.42	0.05	0.44	0.51	0.02	0.44	0.54	0.01	0.45	0.54
25-29, F	0.57	0.27	0.17	0.31	0.37	0.32	0.13	0.42	0.45	0.05	0.44	0.5	0.02	0.46	0.52
30-34, M	0.35	0.42	0.23	0.32	0.38	0.3	0.29	0.33	0.37	0.27	0.29	0.45	0.24	0.25	0.51
30-34, F	0.62	0.24	0.15	0.64	0.18	0.18	0.66	0.13	0.21	0.66	0.1	0.24	0.65	0.07	0.28
35-39, M	0.25	0.45	0.3	0.16	0.41	0.42	0.1	0.37	0.52	0.06	0.34	0.6	0.04	0.32	0.64
35-39, F	0.35	0.36	0.29	0.19	0.36	0.45	0.09	0.35	0.56	0.05	0.35	0.61	0.02	0.36	0.62
40-44, M	0.26	0.45	0.29	0.22	0.41	0.38	0.18	0.36	0.46	0.15	0.32	0.53	0.12	0.28	0.6
40-44, F	0.4	0.34	0.26	0.45	0.24	0.31	0.49	0.16	0.35	0.51	0.11	0.38	0.52	0.07	0.41
45-49, M	0.17	0.4	0.43	0.09	0.31	0.6	0.05	0.24	0.71	0.03	0.19	0.78	0.02	0.16	0.83
45-49, F	0.21	0.36	0.43	0.14	0.27	0.59	0.09	0.2	0.7	0.06	0.16	0.78	0.04	0.12	0.84
50-54, M	0.17	0.4	0.43	0.13	0.27	0.61	0.09	0.18	0.73	0.07	0.12	0.82	0.05	0.08	0.87
50-54, F	0.23	0.39	0.38	0.23	0.4	0.38	0.23	0.4	0.37	0.23	0.41	0.36	0.23	0.41	0.35
55-59, M	0.19	0.47	0.33	0.15	0.4	0.45	0.12	0.33	0.55	0.09	0.27	0.64	0.07	0.22	0.71
55-59, F	0.15	0.4	0.44	0.11	0.42	0.47	0.08	0.42	0.5	0.05	0.43	0.52	0.04	0.43	0.53
60-64, M	0.17	0.48	0.35	0.07	0.43	0.5	0.03	0.39	0.58	0.01	0.37	0.62	0	0.37	0.63
60-64, F	0.15	0.41	0.44	0.1	0.45	0.45	0.07	0.48	0.45	0.05	0.5	0.45	0.03	0.52	0.45
65-69, M	0.17	0.48	0.35	0.07	0.43	0.5	0.03	0.39	0.58	0.01	0.37	0.62	0	0.37	0.63
65-69, F	0.15	0.41	0.44	0.1	0.45	0.45	0.07	0.48	0.45	0.05	0.5	0.45	0.03	0.52	0.45
70-74, M	0.17	0.48	0.35	0.07	0.43	0.5	0.03	0.39	0.58	0.01	0.37	0.62	0	0.37	0.63
70-74, F	0.15	0.41	0.44	0.1	0.45	0.45	0.07	0.48	0.45	0.05	0.5	0.45	0.03	0.52	0.45
75+, M	0.17	0.48	0.35	0.07	0.43	0.5	0.03	0.39	0.58	0.01	0.37	0.62	0	0.37	0.63
75+, F	0.15	0.41	0.44	0.1	0.45	0.45	0.07	0.48	0.45	0.05	0.5	0.45	0.03	0.52	0.45

**Projected BMI distribution in Oman 2010-2050**

	2010			2020			2030			2040			2050		
	<25	25-30	>30	<25	25-30	>30	<25	25-30	>30	<25	25-30	>30	<25	25-30	>30
20-24, M	0.48	0.36	0.16	0.32	0.45	0.23	0.19	0.52	0.29	0.1	0.55	0.35	0.05	0.55	0.4
20-24, F	0.53	0.26	0.21	0.5	0.27	0.23	0.46	0.29	0.26	0.42	0.3	0.28	0.38	0.31	0.31
25-29, M	0.48	0.36	0.16	0.32	0.45	0.23	0.19	0.52	0.29	0.1	0.55	0.35	0.05	0.55	0.4
25-29, F	0.53	0.26	0.21	0.5	0.27	0.23	0.46	0.29	0.26	0.42	0.3	0.28	0.38	0.31	0.31
30-34, M	0.29	0.37	0.33	0.19	0.35	0.46	0.12	0.33	0.55	0.08	0.31	0.61	0.05	0.3	0.65
30-34, F	0.25	0.31	0.43	0.19	0.3	0.51	0.13	0.29	0.58	0.09	0.27	0.64	0.06	0.25	0.68
35-39, M	0.29	0.37	0.33	0.19	0.35	0.46	0.12	0.33	0.55	0.08	0.31	0.61	0.05	0.3	0.65
35-39, F	0.25	0.31	0.43	0.19	0.3	0.51	0.13	0.29	0.58	0.09	0.27	0.64	0.06	0.25	0.68
40-44, M	0.23	0.46	0.32	0.13	0.48	0.39	0.07	0.48	0.45	0.04	0.48	0.49	0.02	0.47	0.51
40-44, F	0.15	0.27	0.58	0.08	0.23	0.69	0.04	0.2	0.76	0.02	0.18	0.8	0.01	0.16	0.83
45-49, M	0.23	0.46	0.32	0.13	0.48	0.39	0.07	0.48	0.45	0.04	0.48	0.49	0.02	0.47	0.51
45-49, F	0.15	0.27	0.58	0.08	0.23	0.69	0.04	0.2	0.76	0.02	0.18	0.8	0.01	0.16	0.83
50-54, M	0.32	0.36	0.32	0.21	0.36	0.43	0.13	0.35	0.52	0.08	0.34	0.58	0.05	0.34	0.61
50-54, F	0.44	0.27	0.29	0.46	0.25	0.29	0.48	0.22	0.3	0.5	0.2	0.31	0.51	0.18	0.31
55-59, M	0.32	0.36	0.32	0.21	0.36	0.43	0.13	0.35	0.52	0.08	0.34	0.58	0.05	0.34	0.61
55-59, F	0.44	0.27	0.29	0.46	0.25	0.29	0.48	0.22	0.3	0.5	0.2	0.31	0.51	0.18	0.31
60-64, M	0.38	0.33	0.28	0.24	0.35	0.41	0.14	0.35	0.51	0.08	0.35	0.57	0.04	0.36	0.59
60-64, F	0.34	0.35	0.3	0.27	0.4	0.33	0.21	0.44	0.35	0.16	0.47	0.37	0.12	0.5	0.39
65-69, M	0.38	0.33	0.28	0.24	0.35	0.41	0.14	0.35	0.51	0.08	0.35	0.57	0.04	0.36	0.59
65-69, F	0.34	0.35	0.3	0.27	0.4	0.33	0.21	0.44	0.35	0.16	0.47	0.37	0.12	0.5	0.39
70-74, M	0.32	0.37	0.31	0.11	0.37	0.51	0.04	0.4	0.55	0.02	0.44	0.54	0.01	0.47	0.53
70-74, F	0.42	0.26	0.33	0.26	0.2	0.55	0.17	0.17	0.65	0.12	0.16	0.71	0.09	0.16	0.75
75+, M	0.32	0.37	0.31	0.11	0.37	0.51	0.04	0.4	0.55	0.02	0.44	0.54	0.01	0.47	0.53
75+, F	0.42	0.26	0.33	0.26	0.2	0.55	0.17	0.17	0.65	0.12	0.16	0.71	0.09	0.16	0.75

**Projected BMI distribution in Saudi Arabia**

	2010			2020			2030			2040			2050		
	<25	25-30	>30	<25	25-30	>30	<25	25-30	>30	<25	25-30	>30	<25	25-30	>30
20-24, M	0.6	0.19	0.21	0.59	0.14	0.27	0.56	0.11	0.33	0.53	0.08	0.39	0.5	0.06	0.44
20-24, F	0.58	0.22	0.19	0.61	0.2	0.19	0.64	0.17	0.19	0.67	0.15	0.18	0.69	0.13	0.18
25-29, M	0.22	0.45	0.33	0.09	0.47	0.44	0.03	0.47	0.49	0.01	0.47	0.52	0	0.48	0.52
25-29, F	0.25	0.28	0.46	0.15	0.27	0.58	0.08	0.26	0.66	0.04	0.26	0.7	0.02	0.26	0.72
30-34, M	0.21	0.47	0.32	0.13	0.49	0.37	0.08	0.51	0.42	0.04	0.51	0.45	0.02	0.51	0.47
30-34, F	0.29	0.29	0.42	0.29	0.27	0.44	0.29	0.25	0.46	0.29	0.23	0.48	0.29	0.21	0.5
35-39, M	0.19	0.43	0.38	0.1	0.44	0.46	0.05	0.43	0.52	0.03	0.42	0.55	0.01	0.42	0.57
35-39, F	0.19	0.29	0.52	0.14	0.26	0.6	0.1	0.24	0.66	0.07	0.22	0.7	0.05	0.21	0.74
40-44, M	0.14	0.48	0.38	0.07	0.51	0.42	0.04	0.52	0.45	0.02	0.52	0.47	0.01	0.51	0.48
40-44, F	0.1	0.29	0.61	0.06	0.27	0.67	0.03	0.26	0.72	0.02	0.24	0.74	0.01	0.23	0.76
45-49, M	0.12	0.53	0.36	0.05	0.56	0.38	0.02	0.58	0.4	0.01	0.58	0.41	0	0.57	0.43
45-49, F	0.08	0.29	0.63	0.04	0.26	0.7	0.02	0.25	0.74	0.01	0.23	0.76	0	0.22	0.77
50-54, M	0.18	0.44	0.38	0.11	0.43	0.46	0.07	0.41	0.52	0.04	0.4	0.56	0.02	0.39	0.59
50-54, F	0.1	0.27	0.64	0.04	0.23	0.73	0.02	0.2	0.78	0.01	0.17	0.82	0	0.15	0.84
55-59, M	0.18	0.46	0.36	0.11	0.46	0.43	0.07	0.45	0.49	0.04	0.44	0.52	0.02	0.43	0.55
55-59, F	0.13	0.27	0.6	0.07	0.23	0.69	0.04	0.2	0.75	0.02	0.18	0.8	0.01	0.16	0.83
60-64, M	0.14	0.52	0.34	0.05	0.54	0.41	0.02	0.53	0.45	0.01	0.52	0.48	0	0.51	0.49
60-64, F	0.1	0.29	0.61	0.04	0.26	0.71	0.01	0.23	0.75	0.01	0.22	0.78	0	0.21	0.79
65-69, M	0	0.62	0.38	0	0.55	0.45	0	0.52	0.48	0	0.51	0.49	0	0.5	0.5
65-69, F	0.01	0.59	0.39	0	0.56	0.44	0	0.53	0.47	0	0.51	0.49	0	0.51	0.49
70-74, M	0	0.62	0.38	0	0.55	0.45	0	0.52	0.48	0	0.51	0.49	0	0.5	0.5
70-74, F	0.01	0.59	0.39	0	0.56	0.44	0	0.53	0.47	0	0.51	0.49	0	0.51	0.49
75+, M	0	0.62	0.38	0	0.55	0.45	0	0.52	0.48	0	0.51	0.49	0	0.5	0.5
75+, F	0.01	0.59	0.39	0	0.56	0.44	0	0.53	0.47	0	0.51	0.49	0	0.51	0.49



**Projected BMI distribution in Turkey 2010-2050**

	2010			2020			2030			2040			2050		
	<25	25-30	>30	<25	25-30	>30	<25	25-30	>30	<25	25-30	>30	<25	25-30	>30
20-24, M	0.76	0.2	0.04	0.82	0.15	0.03	0.87	0.11	0.02	0.9	0.08	0.01	0.93	0.06	0.01
20-24, F	0.88	0.1	0.02	0.96	0.03	0	0.99	0.01	0	1	0	0	1	0	0
25-29, M	0.61	0.31	0.08	0.54	0.35	0.11	0.47	0.38	0.15	0.4	0.41	0.19	0.34	0.42	0.24
25-29, F	0.68	0.28	0.04	0.69	0.3	0.01	0.68	0.31	0	0.67	0.32	0	0.66	0.34	0
30-34, M	0.35	0.55	0.1	0.27	0.68	0.04	0.21	0.77	0.02	0.16	0.83	0.01	0.12	0.87	0
30-34, F	0.53	0.38	0.09	0.61	0.37	0.02	0.63	0.37	0	0.62	0.38	0	0.6	0.4	0
35-39, M	0.26	0.62	0.12	0.13	0.8	0.07	0.06	0.9	0.04	0.03	0.95	0.02	0.01	0.97	0.01
35-39, F	0.52	0.36	0.12	0.63	0.34	0.03	0.66	0.33	0.01	0.66	0.34	0	0.65	0.35	0
40-44, M	0.21	0.61	0.18	0.13	0.78	0.09	0.08	0.87	0.05	0.05	0.93	0.03	0.03	0.96	0.01
40-44, F	0.46	0.42	0.12	0.57	0.42	0.01	0.56	0.44	0	0.54	0.46	0	0.52	0.48	0
45-49, M	0.17	0.62	0.21	0.09	0.78	0.14	0.04	0.87	0.09	0.02	0.92	0.06	0.01	0.95	0.04
45-49, F	0.29	0.52	0.19	0.36	0.6	0.04	0.41	0.58	0.01	0.45	0.55	0	0.47	0.53	0
50-54, M	0.24	0.54	0.22	0.2	0.68	0.12	0.16	0.77	0.07	0.13	0.83	0.04	0.11	0.87	0.02
50-54, F	0.06	0.32	0.63	0.02	0.28	0.7	0	0.25	0.74	0	0.23	0.77	0	0.21	0.79
55-59, M	0.27	0.47	0.25	0.26	0.56	0.18	0.24	0.64	0.12	0.22	0.7	0.08	0.21	0.74	0.05
55-59, F	0.05	0.3	0.65	0.01	0.25	0.73	0	0.22	0.78	0	0.19	0.8	0	0.18	0.82
60-64, M	0.23	0.55	0.23	0.15	0.69	0.17	0.09	0.79	0.12	0.05	0.86	0.08	0.03	0.91	0.06
60-64, F	0.05	0.28	0.67	0.01	0.19	0.8	0	0.13	0.87	0	0.09	0.91	0	0.07	0.93
65-69, M	0.23	0.55	0.23	0.15	0.69	0.17	0.09	0.79	0.12	0.05	0.86	0.08	0.03	0.91	0.06
65-69, F	0.05	0.28	0.67	0.01	0.19	0.8	0	0.13	0.87	0	0.09	0.91	0	0.07	0.93
70-74, M	0.4	0.46	0.15	0.35	0.55	0.1	0.31	0.62	0.06	0.27	0.69	0.04	0.24	0.74	0.03
70-74, F	0.16	0.27	0.57	0.07	0.18	0.75	0.03	0.13	0.85	0.01	0.09	0.9	0	0.06	0.94
75+, M	0.4	0.46	0.15	0.35	0.55	0.1	0.31	0.62	0.06	0.27	0.69	0.04	0.24	0.74	0.03
75+, F	0.16	0.27	0.57	0.07	0.18	0.75	0.03	0.13	0.85	0.01	0.09	0.9	0	0.06	0.94

**Annex 5 Incidence, mortality, survival data per 100,000 of the population in 2010**

**Bahrain incidence per 100,000**

breast cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0	0	0	0	0	0	0	0	0
F	0	18.2	99.3	129.4	170.1	134.2	153.1	187.1	79.5	106.3
colorectal cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	1.3	2.4	13	20.5	29.6	109.7	31.6	74.7	96.1
F	0	1.3	8.3	18.5	10.6	50.3	21.9	26.7	39.7	35.4
coronary heart disease										
AgeGp	0-34	35-44	45-54	55-64	65-74	>74				
M	0	215.49	457.73	610.1	997.41	805.12				
F	0	74.63	233.69	398.03	662.82	329.89				
diabetes										
AgeGp	0-19	20-34	35-49	50-64	>64					
M	0	848.67	2275.21	3116.33	1593.39					
F	0	804.75	1645.13	2551.72	684.68					
endometrial cancer										
AgeGp	0-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74	
M	0	0	0	0	0	0	0	0	0	0
F	0	4.1	12.3	10.6	33.5	43.8	26.7	0	35.4	
hypertension										
AgeGp	0-18	19-29	30-39	40-49	50-59	60-69	>69			
M	0	3397.91	5251.2	8392.6	8582.81	11830.8	8341.98			
F	0	2631.82	5272.27	8523.89	9016.07	9426.98	4606.9			
kidney cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0	2.4	0	5.1	19.7	36.6	0	37.3	32
F	1	1.3	4.1	6.2	0	0	21.9	0	39.7	39.7
liver cancer										
AgeGp	0-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74	
M	0	2.4	3.2	10.2	9.9	36.6	31.6	37.3	96.1	
F	0	0	6.2	0	0	21.9	0	39.7	35.4	
oesophageal cancer										
AgeGp	0-49	50-54	55-59	60-64	65-69	70-74	>74			
M	0	5.1	0	36.6	31.6	37.3	64.1			
F	0	0	0	0	0	39.7	39.7			
osteoarthritis										
AgeGp	15-24	25-34	35-44	45-54	55-64	65-74	>74			
M	2.14	2.71	3.48	8.8	33.91	20.06	54.11			
F	2.73	12.22	34.63	40.75	52.73	36.24	20.59			
pancreatic cancer										
AgeGp	0-44	45-49	50-54	55-59	60-64	65-69	70-74	>74		
M	0	3.2	5.1	19.7	18.3	31.6	37.3	32		
F	0	0	0	16.8	0	0	0	35.4		
stroke										
AgeGp	0-14	15-24	25-34	35-44	45-54	55-64	65-74	75-84	>84	
M	0	1.87	5.6	12	65.85	181.28	324.45	660.36	1006.93	
F	0	2.21	3.78	25.54	66.53	209.03	366.36	700.56	1120.2	

**Bahrain mortality per 100,000**

breast cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0	0	0	0	0	0	0	0	0
F	0	5	33.1	43.1	53.1	67.1	43.8	53.5	39.7	106.3
colorectal cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0	0	3.2	10.2	9.9	54.9	31.6	74.7	64.1
F	0	1.3	4.1	6.2	0	16.8	43.8	26.7	0	35.4
coronary heart disease										
AgeGp	0-14	15-29	30-44	45-59	60-69	70-79	>79			
M	0	9.72	19.44	43.74	135.35	308.61	1164.04			
F	0	0.49	2.48	9.91	74.92	187.3	711.72			
diabetes										
non terminal										
endometrial cancer										
AgeGp	0-54	55-59	60-64	>64						
M	0	0	0	0						
F	0	16.8	21.9	26.7						
hypertension										
non terminal										
kidney cancer										
AgeGp	0-49	50-54	55-59	60-64	65-69	70-74	>74			
M	0	5.1	19.7	18.3	0	0	32			
F	0	0	0	21.9	0	39.7	39.7			
liver cancer										
AgeGp	0-44	45-49	50-54	55-59	60-64	65-69	70-74	>74		
M	0	3.2	5.1	19.7	18.3	31.6	74.7	96.1		
F	0	6.2	0	0	21.9	0	39.7	35.4		
oesophageal cancer										
AgeGp	0-49	50-54	55-59	60-64	65-69	70-74	>74			
M	0	5.1	9.9	18.3	31.6	37.3	64.1			
F	0	0	0	0	0	39.7	39.7			
osteoarthritis										
non terminal										
pancreatic cancer										
AgeGp	0-44	45-49	50-54	55-59	60-64	65-69	70-74	>74		
M	0	0	0	19.7	0	63.3	37.3	64.1		
F	0	6.2	10.6	0	0	26.7	0	35.4		
stroke										
AgeGp	0-14	15-29	30-44	45-59	60-69	70-79	>79			
M	0.37	1.45	3.61	11.57	61.64	115.58	366.77			
F	0	1.25	3.13	6.89	50.98	119.44	432.61			

## Egypt incidence per 100,000

breast cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0	0	0	0	0	0	0	0	0
F	0	12.9	84.9	102.7	106.5	106.6	101.3	92.5	85.5	157.8
colorectal cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0.1	1.9	5.7	7.1	14.4	7.7	16.4	16.6	23.6	23.8
F	0	1.6	5.4	10	9.4	15.6	11.6	11	24.8	19
coronary heart disease										
AgeGp	0-34	35-44	45-54	55-64	65-74	>74				
M	0	475.71	1010.46	1346.82	2201.84	1777.34				
F	0	258.14	808.36	1376.83	2292.78	1141.11				
diabetes										
AgeGp	0-19	20-34	35-49	50-64	>64					
M	0	751.01	1577.13	2815.15	3371.15					
F	0	969.06	2081.07	3463.31	3407.19					
endometrial cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0	0	0	0	0	0	0	0	0
F	0	0.1	0.8	1.6	4.3	6.3	8.8	10	10.1	11.5
hypertension										
AgeGp	0-18	19-29	30-39	40-49	50-59	60-69	>69			
M	0	3138.74	4495.13	6643.01	7767.06	12141.8	14619.6			
F	0	2725.14	6064.21	9843.4	10438.9	14777.5	12616.6			
kidney cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0.4	0.3	1.3	3.8	10.2	7	8.3	11.5	8.2	7.3
F	0.8	0.4	1.6	2.4	2.9	4	4.3	2.3	4.4	3.3
liver cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0.1	0.8	8.2	17.1	34.6	52.3	72.2	73.5	115.4	78.2
F	0.1	0.5	3.6	6.4	8.6	14.3	14.7	21.1	37	20.2
oesophageal cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0.2	1.7	3.5	4	3.7	9.3	14.6	20.4	9.5
F	0	0.2	1.1	1.1	3.9	6	1.8	5.8	12.6	16.8
osteoarthritis										
AgeGp	15-24	25-34	35-44	45-54	55-64	65-74	>74			
M	2.01	2.66	3	7.78	33.33	23.5	87.25			
F	2.68	13.11	37.71	44.62	59.97	54.96	35.18			
pancreatic cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0.2	1.9	3.4	6.5	8.3	8.9	13.4	26.6	21.8
F	0	0.2	1	2.2	2.2	1.9	9.4	8.8	14.7	7.6
stroke										
AgeGp	0-14	15-24	25-34	35-44	45-54	55-64	65-74	75-84	>84	
M	0	7.95	23.84	51.08	280.36	771.84	1381.37	2811.56	4287.14	
F	0	7.91	13.56	91.52	238.39	749.08	1312.87	2510.49	4014.3	

## Egypt mortality per 100,000

breast cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0	0	0	0	0	0	0	0	0
F	0	4	31.2	42.2	66.9	67.3	62.4	61.9	56.6	132.9
colorectal cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0.2	1.1	3.9	5	10.2	5.8	12.3	14.3	21.6	26.4
F	0	0.9	3.4	6.7	6.7	11.9	9.7	9.3	23.5	22.2
coronary heart disease										
AgeGp	0-14	15-29	30-44	45-59	60-69	70-79	>79			
M	0.54	8.3	37.36	74.72	314.22	716.42	2388.08			
F	0.39	2.25	9	47.25	267.07	625.51	2319.3			
diabetes										
non terminal										
endometrial cancer										
AgeGp	0-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74	
M	0	0	0	0	0	0	0	0	0	
F	0	0.1	0.2	0.6	1.4	2.7	3.7	4.2	7.2	
hypertension										
non terminal										
kidney cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0.4	0.2	0.8	2.8	7.8	5.6	7.2	9	7.4	6.6
F	1	0.3	0.9	1.6	1.6	2.6	3.4	1.6	3.9	3
liver cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0.1	0.6	7.7	17.3	32.4	47.6	68.6	73.8	125	80.4
F	0.1	0.3	2.5	5.2	9.9	15.1	18.2	21.6	38.7	16.3
oesophageal cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0.1	1.5	3.5	3.4	3.6	8.8	13.6	21	10.3
F	0	0.1	1	0.8	3.4	5.7	1.7	5.5	12.2	18
osteoarthritis										
non terminal										
pancreatic cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0.2	1.7	3.1	6.3	8	8.5	13.1	27.2	22
F	0	0.2	0.9	2.2	2.1	1.8	8.9	8.8	14.9	8.2
stroke										
AgeGp	0-14	15-29	30-44	45-59	60-69	70-79	>79			
M	6.14	13.02	26.05	58.61	286.57	503.43	1146.27			
F	4.32	5.91	12.31	31.01	265.76	504.94	1284.49			

## Iran incidence per 100,000

breast cancer											
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74	
M	0	0	0	0	0	0	0	0	0	0	
F	0	6	36.2	54.9	61.2	56.1	50.6	47.2	43.6	53.3	
colorectal cancer											
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74	
M	0	1.8	7.9	11.1	20.1	24	29	40.9	53.7	74.5	
F	0	1.2	5.7	8.1	15.8	20	25.4	28.5	34	51.3	
coronary heart disease											
AgeGp	0-34	35-44	45-54	55-64	65-74	>74					
M	0	552.7	1174	1564.8	2558.2	2065					
F	0	271.6	850.5	1448.6	2412.3	1200.6					
diabetes											
AgeGp	0-19	20-34	35-49	50-64	>64						
M	0	509.89	1110.5	1846.9	1927.2						
F	0	590.23	1285.5	2137.9	2230.8						
endometrial cancer											
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74	
M	0	0	0	0	0	0	0	0	0	0	
F	0	0.2	2	2.7	4.4	6.6	8.2	8.6	7.1	6	
hypertension											
AgeGp	0-18	19-29	30-39	40-49	50-59	60-69	>69				
M	0	2691.9	3596.8	5274.6	6147.1	8842.7	10302				
F	0	2172.1	4500.5	7291.2	7761.2	10919	9451.5				
kidney cancer											
AgeGp	0-12	13-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0.5	0.2	0.2	2	2.9	9.7	6.1	8.2	12.9	13.7	22.5
F	0.4	0.4	0.2	1.3	2.2	1.9	2.9	5.4	6.6	5.1	4.7
liver cancer											
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74	
M	0.1	0.2	1.1	2.4	6.7	4.4	12.4	14.6	13.7	34	
F	0.1	0.1	0.8	1.6	1.3	4.8	3.7	7.6	13.8	14.4	
oesophageal cancer											
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74	
M	0	0.4	3.2	6.3	13.6	16.5	27.7	42.9	63.4	84.3	
F	0	0.5	3	5.6	10.7	18.3	29.6	33.9	51.9	52.4	
osteoarthritis											
AgeGp	15-24	25-34	35-44	45-54	55-64	65-74	>74				
M	1.87	2.16	2.59	6.59	27.02	18.46	68.38				
F	2.5	11.22	32.53	38	50.72	46.64	29.88				
pancreatic cancer											
AgeGp	0-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74		
M	0	0.6	1.7	3.1	4.3	5.7	10.7	12	14.3		
F	0	0.8	0.8	2	3.8	3.3	5.1	7.7	14.1		
stroke											
AgeGp	0-14	15-24	25-34	35-44	45-54	55-64	65-74	75-84	>84		
M	0	7	21	45	247	680	1217	2477	3777		
F	0	7	12	81	211	663	1162	2222	3553		

## Iran mortality per 100,000

breast cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0	0	0	0	0	0	0	0	0
F	0	1.7	12	20.4	34.8	32.1	28.2	28.5	26.2	40.6
colorectal cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0.9	4.7	6.9	12.4	15.7	19	30.5	42.6	71.3
F	0	0.6	3.1	4.7	9.7	13.2	18.1	20.9	27.7	51.5
coronary heart disease										
AgeGp	0-14	15-29	30-44	45-59	60-69	70-79	>79			
M	0.35	7.38	29.53	66.45	392.34	980.85	3596.46			
F	0.13	5.7	10.69	46.31	253.08	683.32	2720.64			
diabetes										
non terminal										
endometrial cancer										
AgeGp	0-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74	
M	0	0	0	0	0	0	0	0	0	
F	0	0.2	0.3	0.7	1.7	2.8	3.5	3.1	4.2	
hypertension										
non terminal										
kidney cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0.4	0.1	1.1	1.9	6.4	4.3	6.2	9	11.1	17.8
F	0.4	0.1	0.7	1.4	1.1	1.8	4	4.7	4.3	4
liver cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0.1	0.2	1	2.4	6.2	3.9	11.5	14.4	14.6	34.2
F	0	0.1	0.6	1.3	1.6	5.1	4.9	8.1	14.7	12.1
oesophageal cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0.3	2.8	6	11	15.3	24.9	38.2	62.3	86.7
F	0	0.5	2.6	4.1	9.3	17	27.8	31.7	49.7	54.9
osteoarthritis										
non terminal										
pancreatic cancer										
AgeGp	0-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74	
M	0	0.6	1.5	3	4	5.5	10.4	12.2	14.3	
F	0	0.7	0.8	1.8	3.6	3.1	5.1	7.7	14.9	
stroke										
AgeGp	0-14	15-29	30-44	45-59	60-69	70-79	>79			
M	0.16	1.19	4.77	20.86	175.41	438.52	1827.14			
F	0.12	0.77	3.85	23.13	145.46	374.04	1558.5			

## Jordan incidence per 100,000

breast cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0	0	0	0	0	0	0	0	0
F	0	10.8	87.6	122.5	131.9	149	169.5	144.2	195.7	141.1
colorectal cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0.1	1.9	6.5	20	36.8	59.5	89.3	113.2	147.2	129.8
F	0.1	1.7	12.7	21.9	40.3	39.1	70.9	73.3	82.9	73.4
coronary heart disease										
AgeGp	0-34	35-44	45-54	55-64	65-74	>74				
M	0	540.83	1148.8	1531.21	2503.28	2020.67				
F	0	174.16	545.37	928.89	1546.84	769.86				
diabetes										
AgeGp	0-19	20-34	35-49	50-64	>64					
M	0	680.84	2141.1	3362.68	4489.54					
F	0	927.5	2019.07	3747.94	3811.14					
endometrial cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0	0	0	0	0	0	0	0	0
F	0	0.3	1.9	7.9	17.1	21.1	32.9	57.2	49.8	25.4
hypertension										
AgeGp	0-18	19-29	30-39	40-49	50-59	60-69	>69			
M	0	2932.04	4945.72	8181.18	8769.44	14261.4	18132.5			
F	0	2625.82	5929.75	10023.8	11135.3	15693.5	13817.2			
kidney cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0.5	0.3	3.6	5.8	5.9	16.8	20.6	14.7	16.4	11.8
F	0.5	0.1	0.6	1.7	3.7	4.5	12.1	11.4	13.3	2.8
liver cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0.2	0.1	0.6	0.8	4.7	6.1	13.7	16.8	19.6	8.8
F	0.3	0.1	0.6	0	2.4	1.5	5.2	4.6	3.3	2.8
oesophageal cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0.1	0.6	0.8	1.2	3.1	3.4	4.2	6.5	8.8
F	0	0.1	0	0.9	1.2	3	3.5	6.9	3.3	5.6
osteoarthritis										
AgeGp	15-24	25-34	35-44	45-54	55-64	65-74	>74			
M	2.13	2.45	3.44	9.03	37.17	27.54	103.69			
F	2.66	12.98	38.12	45.95	62.83	57.83	37.36			
pancreatic cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0.1	0.1	5.3	7.5	8.3	10.7	13.7	23.1	39.3	14.7
F	0	0.2	0	2.6	3.7	7.5	12.1	11.4	19.9	19.8
stroke										
AgeGp	0-14	15-24	25-34	35-44	45-54	55-64	65-74	75-84	>84	
M	0	8.9	26.7	57.21	314.01	864.47	1547.15	3148.96	4801.63	
F	0	8.22	14.09	95.09	247.71	778.35	1364.18	2608.61	4171.19	



## Jordan mortality per 100,000

breast cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0	0	0	0	0	0	0	0	0
F	0	3.1	30.5	47.2	78.2	88.8	98.6	91.6	122.7	112.9
colorectal cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0.1	0.9	4.2	12.5	23.7	39.7	60.1	88	121	129.8
F	0.1	0.9	7	13.1	25.7	27.1	53.6	57.2	73	79
coronary heart disease										
AgeGp	0-14	15-29	30-44	45-59	60-69	70-79	>79			
M	0	12.6	37.8	126.02	275.33	676.25	2801.59			
F	0	0.81	8.12	32.47	157.65	403.58	1608			
diabetes										
non terminal										
endometrial cancer										
AgeGp	0-44	45-49	50-54	55-59	60-64	65-69	70-74	>74		
M	0	0	0	0	0	0	0	0		
F	0	0.9	2.4	4.5	10.4	20.6	19.9	16.9		
hypertension										
non terminal										
kidney cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0.5	0.2	1.8	4.2	4.7	12.2	17.2	10.5	13.1	8.8
F	0.6	0.1	0.6	0.9	2.4	3	8.6	6.9	10	2.8
liver cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0.2	0.1	0.6	0.8	4.7	6.1	13.7	16.8	19.6	8.8
F	0.1	0	0.6	0	3.7	1.5	6.9	4.6	3.3	2.8
oesophageal cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0.1	0.6	0.8	1.2	3.1	3.4	4.2	6.5	8.8
F	0	0.1	0	0.9	1.2	3	3.5	6.9	3.3	5.6
osteoarthritis										
non terminal										
pancreatic cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0.1	0.1	4.7	6.7	8.3	10.7	13.7	23.1	39.3	14.7
F	0	0.1	0	2.6	3.7	7.5	12.1	11.4	19.9	22.6
stroke										
AgeGp	0-14	15-29	30-44	45-59	60-69	70-79	>79			
M	0.15	1.62	8.09	32.35	191.24	478.11	1912.44			
F	0.46	10.72	10.72	10.72	755.58	755.58	755.58			

## Kuwait incidence per 100,000

breast cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0	0	0	0	0	0	0	0	0
F	0	12.2	68.4	126.9	133.8	159.8	160.5	201.9	137	159.3
colorectal cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	1.5	2.9	6.9	11.2	15.8	45.7	60.6	86.9	205.2
F	0	2.1	11.6	14.3	33.4	28	41.6	96.5	68.5	115.8
coronary heart disease										
AgeGp	0-34	35-44	45-54	55-64	65-74	>74				
M	0	302.62	642.79	856.76	1400.67	1130.64				
F	0	147.34	461.4	785.87	1308.68	651.33				
diabetes										
AgeGp	0-19	20-34	35-49	50-64	>64					
M	0	1123.65	2503.04	3938.52	3534.83					
F	0	1031.43	2091.19	3851.61	3413.12					
endometrial cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0	0	0	0	0	0	0	0	0
F	0	0.2	1.2	3.2	9.6	28	29.7	17.6	13.7	14.5
hypertension										
AgeGp	0-18	19-29	30-39	40-49	50-59	60-69	>69			
M	0	4294.24	6043.37	8666.12	10035.1	13378.7	15324.1			
F	0	2997.19	6239.71	9925.25	11203	15772	12723.1			
kidney cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0.6	0.2	1.8	2.6	2.5	6.8	24.6	38.6	48.3	73.3
F	1.2	0.9	1.2	-1	2.4	8	17.8	8.8	41.1	43.4
liver cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0.3	0.9	0.6	4.3	10	15.8	28.2	38.6	38.6	117.3
F	0.6	0.3	0	3.2	7.2	8	11.9	35.1	41.1	72.4
oesophageal cancer										
AgeGp	0-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74	
M	0	0.6	0.9	1.2	2.3	3.5	11	9.7	44	
F	0	0	0	0	4	5.9	8.8	13.7	14.5	
osteoarthritis										
AgeGp	15-24	25-34	35-44	45-54	55-64	65-74	>74			
M	2.34	3.3	3.74	9.35	37.72	25.17	93.14			
F	2.81	13.65	38.21	45.37	63.95	56.09	35.72			
pancreatic cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0.1	0.6	1.7	2.5	4.5	10.6	16.5	29	58.6
F	0	0	1.2	6.3	7.2	8	23.8	61.4	27.4	72.4
stroke										
AgeGp	0-14	15-24	25-34	35-44	45-54	55-64	65-74	75-84	>84	
M	0	5.18	15.54	33.3	182.8	503.26	900.69	1833.21	2795.33	
F	0	5.42	9.29	62.73	163.41	513.47	899.93	1720.87	2751.69	

## Kuwait mortality per 100,000

breast cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0	0	0	0	0	0	0	0	0
F	0	1	7	23.8	40.6	59.9	101.1	70.2	54.8	86.9
colorectal cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0.1	1.2	0.9	2.5	9	14.1	71.7	77.2	190.6
F	0	0.5	2.3	3.2	9.6	16	41.6	26.3	82.2	173.8
coronary heart disease										
AgeGp	0-14	15-29	30-44	45-59	60-69	70-79	>79			
M	0	6.82	27.27	68.16	159.78	386.57	1329.81			
F	0.33	0.96	4.83	14.48	150.72	346.64	1228.32			
diabetes										
non terminal										
endometrial cancer										
AgeGp	0-39	40-44	45-54	55-59	60-64	>64				
M	0	0	0	0	0	0				
F	0	1.2	0	8	5.9	8.8				
hypertension										
non terminal										
kidney cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0	0	0	0	0	7	27.6	48.3	58.6
F	0.3	0.2	1.2	1.6	2.4	4	0	8.8	13.7	14.5
liver cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0.1	0.6	4.3	6.2	13.5	21.1	49.6	86.9	190.6
F	0	0	1.2	1.6	2.4	8	17.8	52.7	82.2	115.8
oesophageal cancer										
AgeGp	0-14	15-39	40-49	50-54	55-59	60-64	65-69	70-74	>74	
M	0	0.1	0	0	0	3.5	5.5	9.7	73.3	
F	0	0	0	2.4	4	0	0	0	14.5	
osteoarthritis										
non terminal										
pancreatic cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0	0	0.9	1.2	2.3	10.6	16.5	29	117.3
F	0	0.5	1.2	3.2	7.2	8	17.8	17.6	27.4	72.4
stroke										
AgeGp	0-14	15-29	30-44	45-59	60-69	70-79	>79			
M	0.29	0.66	5.96	16.55	102.35	233.93	774.9			
F	0.32	1.19	4.18	14.92	119.34	270.51	907			

## Lebanon incidence per 100,000

### breast cancer

AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0	0	0	0	0	0	0	0	0
F	0	18.1	104.6	148.1	153.2	179.9	192.7	180.9	147.8	128.3

### colorectal cancer

AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	1.5	10.7	16.5	35.9	35.7	66.6	74.1	94.9	83.8
F	0	2.7	13.3	15.6	33.2	40.3	45.2	62.6	79.3	48.1

### coronary heart disease

AgeGp	0-34	35-44	45-54	55-64	65-74	>74
M	0	530.87	1127.6	1503	2457.2	1983.5
F	0	197.98	619.98	1056	1758.5	875.18

### diabetes

AgeGp	0-19	20-34	35-49	50-64	>64
M	0	796.13	1851.5	3151.6	3292
F	0	485.09	1130.7	2357.5	2459.3

### endometrial cancer

AgeGp	0-13	14-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0	0	0	0	0	0	0	0	0	0
F	0	-1	0.3	3.3	6.7	9.9	16.6	24.1	27.8	25.7	19.6

### hypertension

AgeGp	0-18	19-29	30-39	40-49	50-59	60-69	>69
M	0	3433.8	4805.7	7268.9	8734.9	12123	14604
F	0	2337.2	3921.5	6902.8	8189.9	11981	10226

### kidney cancer

AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0.4	0.2	2.3	4.3	6.2	19.8	12	17.6	20.3	12.3
F	0.6	0.8	2.7	4.4	4.5	10.7	10.5	12.2	8.6	3.6

### liver cancer

AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0.2	0.8	1.7	3.1	5.3	13.7	11.7	24.9	14.3
F	0.2	0.3	1.3	2.2	2.7	2.4	9	8.7	8.6	14.3

### oesophageal cancer

AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0.2	0.8	0.9	3.1	2.6	6.8	7.8	11.3	14.3
F	0	0.1	0.7	0	1.8	1.2	3	1.7	2.1	7.1

### osteoarthritis

AgeGp	15-24	25-34	35-44	45-54	55-64	65-74	>74
M	2.13	2.81	3.23	8.76	34.65	24.17	89.74
F	2.66	10.46	30.29	38.33	53.85	49.48	31.67

### pancreatic cancer

AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0.1	2.3	5.2	5.1	11.9	17.1	9.8	31.6	26.6
F	0	0.1	1.3	2.2	4.5	5.9	7.5	17.4	34.3	26.7

### stroke

AgeGp	0-14	15-24	25-34	35-44	45-54	55-64	65-74	75-84	>84
M	0	5.04	15.13	32.43	178	490.03	877.02	1785	2721.9
F	0	4.01	6.88	46.43	120.94	380.01	666.02	1273.6	2036.5

## Lebanon mortality per 100,000

breast cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0	0	0	0	0	0	0	0	0
F	0	4.9	33.3	53.3	84.2	99.4	103.9	106.1	85.7	94.4
colorectal cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0.8	6.1	10.4	22.6	23.8	42.7	54.6	74.6	79.7
F	0	1.3	7.3	8.9	20.6	27.2	33.1	47	66.4	49.9
coronary heart disease										
AgeGp	0-14	15-29	30-44	45-59	60-69	70-79	>79			
M	0.15	6.67	26.67	126.7	326.11	826.16	3152.43			
F	0.09	3.93	7.87	35.4	185.07	481.18	2023.42			
diabetes										
non terminal										
endometrial cancer										
AgeGp	0-39	40-49	50-54	55-59	60-64	65-69	70-74	>74		
M	0	0	0	0	0	0	0	0		
F	0	0.7	0.9	3.6	7.5	10.4	10.7	12.5		
hypertension										
non terminal										
kidney cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0.4	0.1	1.5	2.6	4.1	14.5	8.5	11.7	15.8	10.2
F	0.8	0.6	1.3	3	2.7	7.1	7.5	8.7	8.6	3.6
liver cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0.2	0.8	1.7	3.1	5.3	12	11.7	27.1	14.3
F	0.2	0.2	0.7	2.2	3.6	2.4	12	8.7	8.6	12.5
oesophageal cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0.2	0.8	0.9	2.1	2.6	6.8	7.8	11.3	14.3
F	0	0.1	0.7	0	1.8	1.2	3	1.7	2.1	7.1
osteoarthritis										
non terminal										
pancreatic cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0.1	2.3	4.3	5.1	11.9	17.1	9.8	31.6	26.6
F	0	0.1	1.3	2.2	3.6	5.9	7.5	17.4	34.3	28.5
stroke										
AgeGp	0-14	15-29	30-44	45-59	60-69	70-79	>79			
M	1.42	4.72	9.45	23.62	179.65	359.31	1012.59			
F	0.74	0.91	4.54	11.35	113.44	253.06	820.26			

## Oman incidence per 100,000

### breast cancer

AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0	0	0	0	0	0	0	0	0
F	0	4.7	37	70.5	77.7	124.8	99.3	135.9	106.6	67

### colorectal cancer

AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0.7	2.5	6.7	15	16.6	25.7	51.5	41.8	66.4
F	0.5	1.3	8.8	11	11.5	20.1	36.6	61.8	29.1	33.5

### coronary heart disease

AgeGp	0-34	35-44	45-54	55-64	65-74	>74
M	0	598.92	1272.18	1695.66	2772.13	2237.69
F	0	168.2	526.73	897.14	1493.97	743.55

### diabetes

AgeGp	0-19	20-34	35-49	50-64	>64
M	0	785.55	1828.14	2671.21	2795.14
F	0	818.49	1833.56	1811.73	1698.69

### endometrial cancer

AgeGp	0-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0	0	0	0	0	0	0	0
F	0	1.8	4.4	8.6	8.1	15.7	30.9	9.7	8.4

### hypertension

AgeGp	0-18	19-29	30-39	40-49	50-59	60-69	>69
M	0	3279.91	5047.17	7023.91	7715.04	10540.4	12804.1
F	0	2508.2	5558.3	9167.11	6900.91	9657.19	7779.6

### kidney cancer

AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0.4	0	0	1.1	3.3	7.1	7.4	10.3	16.7	9.5
F	1.1	0.2	0	2.2	0	8.1	0	6.2	29.1	8.4

### liver cancer

AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0.1	1.7	3.4	6.6	11.8	25.7	20.6	50.2	37.9
F	0.7	0.4	0	0	0	4	5.2	18.5	48.5	25.1

### oesophageal cancer

AgeGp	0-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	1.1	1.7	2.4	3.7	5.2	16.7	37.9
F	0	0	2.9	0	5.2	12.4	9.7	16.7

### osteoarthritis

AgeGp	15-24	25-34	35-44	45-54	55-64	65-74	>74
M	2.15	2.68	3.25	7.97	30.45	20.69	78.08
F	2.69	12.17	35.96	39.11	46.45	42.61	26.48

### pancreatic cancer

AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0	0	0	1.7	7.1	7.4	5.2	16.7	19
F	0.2	0	1.8	0	2.9	8.1	5.2	18.5	9.7	8.4

### stroke

AgeGp	0-14	15-24	25-34	35-44	45-54	55-64	65-74	75-84	>84
M	0	4.03	12.08	25.88	142.05	391.05	699.87	1424.48	2172.08
F	0	3.22	5.52	37.25	97.03	304.9	534.38	1021.86	1633.96

## Oman mortality per 100,000

breast cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0	0	0	0	0	0	0	0	0
F	0	1.4	12.3	19.8	40.3	48.3	57.5	55.6	67.8	41.8
colorectal cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0.4	2.5	5.6	10	9.5	18.4	36.1	50.2	56.9
F	0.5	0.5	5.3	4.4	8.6	12.1	20.9	43.3	19.4	25.1
coronary heart disease										
AgeGp	0-14	15-29	30-44	45-59	60-69	70-79	>79			
M	0.09	9.32	55.93	205.09	278.65	687.91	2612.32			
F	0	0.86	7.75	34.42	151.24	371.8	1449.39			
diabetes										
non terminal										
endometrial cancer										
AgeGp	0-59	60-64	65-69	70-74	>74					
M	0	0	0	0	0					
F	0	5.2	6.2	9.7	8.4					
hypertension										
non terminal										
kidney cancer										
AgeGp	0-14	15-44	45-49	50-54	55-59	60-64	65-69	70-74	>74	
M	0.7	0	1.1	1.7	7.1	7.4	5.2	8.4	8.4	
F	0.9	0	0	0	0	0	0	9.7	8.4	
liver cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0	0.8	3.4	6.6	9.5	29.4	46.4	66.9	37.9
F	0.5	0	1.8	2.2	0	8.1	15.7	18.5	58.2	25.1
oesophageal cancer										
AgeGp	0-44	45-49	50-54	55-59	60-64	65-69	70-74	>74		
M	0	2.2	3.3	2.4	0	20.6	25.1	37.9		
F	0	0	2.9	0	0	18.5	0	8.4		
osteoarthritis										
non terminal										
pancreatic cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0	0	0	1.7	7.1	7.4	5.2	33.5	28.4
F	0.2	0	1.8	2.2	5.8	4	10.5	24.7	9.7	8.4
stroke										
AgeGp	0-14	15-29	30-44	45-59	60-69	70-79	>79			
M	0.07	0.96	4.82	19.29	81.1	187.14	692.44			
F	0.12	1.2	2.4	10.18	70.59	161.76	588.22			

## Saudi Arabia incidence per 100,000

breast cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0	0	0	0	0	0	0	0	0
F	0	8.4	47.4	66.6	63.6	61.9	69.2	54.5	46.4	70.9
colorectal cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	1.6	5.1	15.1	16.1	42.8	65.3	82.5	105.8	136.6
F	0	2	8.8	17.2	23.2	27.2	41.1	36.8	46.4	79.2
coronary heart disease										
AgeGp	0-34	35-44	45-54	55-64	65-74	>74				
M	0	595.78	1265.51	1686.77	2757.6	2225.96				
F	0	173.3	542.68	924.3	1539.21	766.06				
diabetes										
AgeGp	0-19	20-34	35-49	50-64	>64					
M	0	988.46	2081.62	3176.06	3722.6					
F	0	1060.44	2013.71	3206.86	2335.23					
endometrial cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0	0	0	0	0	0	0	0	0
F	0	0.3	4	7.3	5.4	19.8	22	23.6	32	15.7
hypertension										
AgeGp	0-18	19-29	30-39	40-49	50-59	60-69	>69			
M	0	3824.83	5477.58	7744.43	8711.59	12886.5	16316.3			
F	0	2918.85	5964.28	9703.23	10013.2	13076.1	10186.5			
kidney cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0.4	0.3	1.7	3.5	3.7	6.6	11.8	9	12.1	24.8
F	0.5	0.3	1.1	2.3	3.7	4	8.4	5.9	12.4	6.6
liver cancer										
AgeGp	0-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74	
M	0.1	0.6	2.3	7.3	12.3	21.6	27	29.7	66.6	
F	0.1	0.6	2.9	3.7	5.7	16.3	14.7	15.5	19	
oesophageal cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0	0.2	0.6	1.1	2.4	5.4	4.9	9.3	24.8
F	0	0.1	0.6	1.4	2	3.1	9	7.4	10.3	33.8
osteoarthritis										
AgeGp	15-24	25-34	35-44	45-54	55-64	65-74	>74			
M	2.11	3.12	3.52	8.82	35.26	27.19	101.97			
F	2.67	13.41	37.43	44.17	58.02	51.21	32.64			
pancreatic cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0.1	0.7	2.1	4.9	11.4	11.3	15.9	18.6	87.9
F	0	0.1	0.8	1.6	7.7	10.1	10.7	31	15.5	44.5
stroke										
AgeGp	0-14	15-24	25-34	35-44	45-54	55-64	65-74	75-84	>84	
M	0	3.93	11.78	25.24	138.56	381.47	682.72	1389.56	2118.84	
F	0	3.16	5.41	36.52	95.14	298.96	523.97	1001.94	1602.12	



### Saudi Arabia mortality per 100,000

breast cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0	0	0	0	0	0	0	0	0
F	0	2.3	15.3	24.2	35.3	34.7	37.7	32.4	26.8	52.8
colorectal cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0.8	2.9	9	9.6	27.1	41.2	58.9	80.7	126.4
F	0	1	4.6	9.7	14.1	18	29.3	26.5	37.1	78.4
coronary heart disease										
AgeGp	0-14	15-29	30-44	45-59	60-69	70-79	>79			
M	0.12	9.41	65.88	207.04	310.78	745.86	2841.37			
F	0	1.85	9.27	37.07	158.49	396.22	1584.89			
diabetes										
non terminal										
endometrial cancer										
AgeGp	0-39	40-44	45-54	55-59	60-64	65-69	70-74	>74		
M	0	0	0	0	0	0	0	0		
F	0	0.5	0.7	4.4	6.8	8.1	12.4	9.1		
hypertension										
non terminal										
kidney cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0.3	0.2	0.8	2.1	2.4	4.5	8.3	5.5	9.3	18.8
F	0.5	0.2	0.5	1.4	1.7	2.2	5.6	3.7	9.3	4.9
liver cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0.1	0.6	2.3	6.7	10.8	20.1	26.3	31.6	67.4
F	0	0	0.5	2.3	4	5.7	19.7	14.7	15.5	14.8
oesophageal cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0	0.2	0.6	0.9	2.1	4.9	4.2	9.3	25.6
F	0	0.1	0.5	0.9	1.7	2.6	8.4	6.6	9.3	34.6
osteoarthritis										
non terminal										
pancreatic cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0	0.6	1.9	4.7	10.8	10.8	15.2	18.6	87.9
F	0	0.1	0.6	1.6	7.1	9.7	10.1	30.2	15.5	47
stroke										
AgeGp	0-14	15-29	30-44	45-59	60-69	70-79	>79			
M	0.11	0.78	6.24	19.5	91.8	222.94	786.84			
F	0.18	1.27	3.17	11.42	75.43	181.03	603.42			

## Turkey incidence per 100,000

### breast cancer

AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0	0	0	0	0	0	0	0	0
F	0	10.6	59	74.7	81.7	77.7	80.4	78.8	91.9	88.8

### colorectal cancer

AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	2.2	12.1	16.1	20.8	40.7	49.6	65.9	104.3	99.3
F	0.1	1.4	5.9	11	21.5	28	34.4	43.5	65.9	66.2

### coronary heart disease

AgeGp	0-34	35-44	45-54	55-64	65-74	>74
M	0	444.37	943.89	1258.09	2056.78	1660.25
F	0	223.07	698.55	1189.79	1981.32	986.1

### diabetes

AgeGp	0-19	20-34	35-49	50-64	>64
M	0	512.01	1347.36	2533.42	2244.56
F	0	359.33	817.45	3214.72	2882.47

### endometrial cancer

AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0	0	0	0	0	0	0	0	0
F	0	0.6	5.2	10.9	18.4	23.3	28.1	29.2	22.1	17

### hypertension

AgeGp	0-18	19-29	30-39	40-49	50-59	60-69	>69
M	0	2625	3950	6325	7575	10975	11150
F	0	1750	3600	5950	9925	14650	11050

### kidney cancer

AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0.7	0.4	2.9	5.5	6.8	10	14.1	19.7	20.6	16.4
F	0.5	0.5	1.5	3.4	2	5.5	9	8.6	9.3	10.6

### liver cancer

AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0.1	0.3	1.7	5.1	7.5	10.9	17.6	21.3	19.2	24.6
F	0	0.3	1	1.3	1.8	4.1	5.8	7.9	10.4	14.8

### oesophageal cancer

AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0.3	2.5	4.5	8.1	11.9	27.2	33.3	44.1	49.7
F	0	0.3	2.4	3.4	9.1	14.9	17.7	20.9	28.5	45.1

### osteoarthritis

AgeGp	15-24	25-34	35-44	45-54	55-64	65-74	>74
M	1.89	2.3	3.05	8.04	32.43	21.48	72.78
F	2.42	10.03	28.45	39.02	60.17	53.43	32.55

### pancreatic cancer

AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0.2	2.2	4.8	8	11.4	19.4	17.6	32.5	26
F	0	0.3	1.5	2.6	2.9	7.4	9.1	15	26.5	21.5

### stroke

AgeGp	0-14	15-24	25-34	35-44	45-54	55-64	65-74	75-84	>84
M	0	9.62	28.87	61.87	339.57	934.86	1673.12	3405.36	5192.59
F	0	7.3	12.51	84.44	219.95	691.12	1211.28	2316.24	3703.69

## Turkey mortality per 100,000

breast cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0	0	0	0	0	0	0	0	0
F	0	2.7	17.7	25.1	41.9	40.1	40.5	43.1	49.6	61.2
colorectal cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	1.1	7.1	9.7	12.5	25.8	31.3	47.4	79.9	91.9
F	0	0.6	3	5.9	12.4	17.4	23.2	30.2	50.4	62.6
coronary heart disease										
AgeGp	0-14	15-29	30-44	45-59	60-69	70-79	>79			
M	0	7.93	31.72	134.82	242.61	606.53	2256.28			
F	0	1.86	9.3	51.14	188.06	493.67	2092.21			
diabetes										
non terminal										
endometrial cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0	0	0	0	0	0	0	0	0
F	0	0.1	0.6	1.3	2.5	5.5	9	11	9.4	11
hypertension										
non terminal										
kidney cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0.6	0.2	1.5	3.5	4.4	6.8	10.4	13.2	15.8	12.5
F	0.6	0.3	0.8	2	1.1	3.2	6.2	5.6	7.5	8.8
liver cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0.1	0.3	1.6	5.1	6.9	9.8	16.5	21	20.6	24.7
F	0	0.1	0.7	1.1	2.2	4.4	7.3	8.2	11.1	12.3
oesophageal cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0.2	2.1	4.3	6.7	11.1	24.8	29.9	43.6	51.4
F	0	0.4	2.1	2.4	7.8	13.6	16.3	19.2	26.8	46.3
osteoarthritis										
non terminal										
pancreatic cancer										
AgeGp	0-14	15-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	>74
M	0	0.1	2.1	4.3	7.8	10.9	18.6	17.2	33.3	26.4
F	0	0.2	1.2	2.5	2.6	7.1	8.4	14.9	26.5	22.8
stroke										
AgeGp	0-14	15-29	30-44	45-59	60-69	70-79	>79			
M	2.1	3.56	17.82	53.45	306.54	620.93	1744.9			
F	1.03	1.68	6.7	23.45	216.48	450.29	1385.5			

### Middle Eastern survival data

breast cancer						
AgeGp	>14					
male Rate	0					
female Rate	0.0497					
male p(5 yr survival)	1					
female p(5 yr survival)	0.78					
colorectal cancer						
AgeGp	>14					
male Rate	0.0989					
female Rate	0.0989					
male p(5 yr survival)	0.61					
female p(5 yr survival)	0.61					
coronary heart disease						
AgeGp	>34					
male Rate	0.2433					
female Rate	0.2433					
male p(5 yr survival)	0.2962					
female p(5 yr survival)	0.2962					
diabetes						
non terminal						
endometrial cancer						
AgeGp	15-39	40-49	50-59	60-69	70-79	>79
male Rate	0	0	0	0	0	0
female Rate	0.0373	0.0349	0.0325	0.0421	0.0685	0.1308
male p(5 yr survival)	1	1	1	1	1	1
female p(5 yr survival)	0.83	0.84	0.85	0.81	0.71	0.52
hypertension						
non terminal						
kidney cancer						
AgeGp	>14					
male Rate	0.1386					
female Rate	0.1427					
male p(5 yr survival)	0.5					
female p(5 yr survival)	0.49					
liver cancer						
AgeGp	>14					
male Rate	0.5791					
female Rate	0.5791					
male p(5 yr survival)	0.0553					
female p(5 yr survival)	0.0553					
oesophageal cancer						
AgeGp	>14					
male Rate	0.5051					
female Rate	0.5051					
male p(5 yr survival)	0.08					
female p(5 yr survival)	0.08					
osteoarthritis						
non terminal						
pancreatic cancer						
AgeGp	15-39	40-49	50-59	60-69	70-79	>79
male Rate	0.4605	0.4605	0.5991	0.6438	0.7824	1
female Rate	0.3544	0.3544	0.5627	0.6438	0.7824	0.921
male p(5 yr survival)	0.1	0.1	0.05	0.04	0.02	0.0067
female p(5 yr survival)	0.17	0.17	0.06	0.04	0.02	0.01

stroke	45-54	55-64	65-74	75-84	>84
AgeGp					
male Rate	0.0155	0.0348	0.0916	0.1824	0.3338
female Rate	0.0155	0.0348	0.0916	0.1824	0.3338
male p1	0.238	0.238	0.238	0.238	0.238
female p1	0.238	0.238	0.238	0.238	0.238
male p(5 yr survival)	0.7162	0.663	0.5282	0.3674	0.2005
female p(5 yr survival)	0.7162	0.663	0.5282	0.3674	0.2005

**Annex 6 Population distribution of each country (<http://www.un.org/esa/population/>)**



